Company Description
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases.
The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency (“AI”) in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially treated with a chelating agent; PKU GOLIKE, medical formula for the dietary management of phenylketonuria (“PKU”); Carglumic Acid, treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (“NAGS”) deficiency; Betaine Anhydrous, for the treatment of homocystinuria; Nitisinone for the treatment of tyrosinemia type 1; and Amglidia for the treatment of neonatal diabetes mellitus products.
It also develops ET-600 for the treatment of central diabetes insipidus; ET-700 for the treatment of treatment of Wilson disease; ET-800; Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis.
Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 13, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Sean Brynjelsen |
Contact Details
Address: 21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7278 United States | |
| Phone | 847 787 7361 |
| Website | etonpharma.com |
Stock Details
| Ticker Symbol | ETON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710340 |
| CUSIP Number | 29772L108 |
| ISIN Number | US29772L1089 |
| Employer ID | 37-1858472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sean E. Brynjelsen | President, Chief Executive Officer and Director |
| James R. Gruber CPA | Chief Financial Officer, Treasurer and Secretary |
| David C. Krempa | Chief Business Officer |
| Danka Radosavljevic | Senior Vice President of Quality and Operations |
| Scott Grossenbach | Senior Vice President of Sales Operations |
| Kevin Guthrie | Executive Vice President of Commercial Operations |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 8-K/A | [Amend] Current report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | 8-K | Current Report |